10 results about "Immunoliposome" patented technology

The invention relates to the technical field of medical materials, in particular to a teralizumab immune sustained-release embolization microsphere and a preparation method thereof.The teralizumab immune sustained-release embolization microsphere comprises a sustained-release microsphere and a modified gel material, teralizumab is loaded on the sustained-release microsphere, and the modified gel material is loaded on the sustained-release microsphere. The modified gel material is coated on the sustained release microspheres; the sustained-release microspheres are prepared from a polylactic acid-glycolic acid copolymer, and tiralizumab is loaded in the sustained-release microspheres through a low-temperature emulsification-phase separation method. The invention relates to an embolism microsphere and a preparation method thereof, and aims to enable the embolism microsphere to be in better contact with a focus part by loading teralizumab on the embolism microsphere and forming coating.

The invention relates to a synthetic route for pterocarpan compounds, to a pterocarpan nanoencapsulated in a liposome or in an immunoliposome functionalized with a monoclonal antibody, to a pharmaceutical composition comprising the liposomes or immunoliposomes, and to use of the pharmaceutical formulation for manufacturing a medicament for the treatment of cancer.

This invention relates to an immunoliposome containing tebuconazole, its preparation method, and its application in anti-breast cancer treatment. The tebuconazole immunoliposome is composed of tebuconazole coated with phospholipids and cholesterol, and modified with trastuzumab. The preparation method of the tebuconazole immunoliposome of this invention is simple and exhibits excellent anti-tumor effects. The novel tebuconazole immunoliposome can overcome the drawback of tebuconazole's non-selectivity for tumor cells, thus enhancing its anti-tumor efficacy. Furthermore, the actively targeted immunoliposome with trastuzumab as a target exhibits significant targeting in vivo, and its anti-tumor effect is significantly different from that of non-targeted liposomes. This invention provides a new avenue for the anti-tumor application of tebuconazole and is of great significance for advancing the clinical application of tebuconazole.

Belongs to the field of application of lipidosome preparations in preparation of tumor drugs, and particularly relates to a T-cell targeted immune lipidosome (TRAFsome). The valence states of the targeting antibody and the immune cell binding antibody are different and are optimized respectively, and the drug encapsulated in the liposome can be an immunomodulator, an anti-cancer drug or a combination thereof.

The application belongs to the technical field of biological medicine, and particularly relates to an immune liposome targeting ganglioside GD2 and mitochondria as well as a preparation method and application thereof. The application couples LX3 and thiolated daratumumab to DSPE-PEG2000 respectively to obtain DSPE-PEG2000-LX3 and DSPE-PEG2000-aGD2, and then is compounded with DSPC and cholesterol to obtain the immune liposome, which has good dispersity, excellent stability and cannot induce cytotoxicity. Cell combination and uptake analysis shows that the immune liposome can specifically target ganglioside GD2 positive tumor cells and then further reach mitochondria thereof. Compared with existing liposomes, the immune liposome provided by the application has double targeting functions of ganglioside GD2 and mitochondria, and can selectively deliver an anti-tumor drug into mitochondria of neuroblastoma cells.

Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.

The present invention relates to the field of uses of liposome formulations in preparation of tumor drugs, and in particular to a T cell-directed immunoliposome (TRAFsome). A targeting antibody and an immune cell engaging antibody have different valencies and are optimized separately, and a drug encapsulated in the liposome can be an immunomodulator, an anti-cancer drug or a combination thereof.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.

An engineered nanobody conjugate is provided, comprising: a Variable Heavy domain of Heavy chain (VHH) nanobody; a peptide single transmembrane domain (STMD); and a peptide linker between the nanobody and the STMD. The invention also provides a method of making an immunoliposome composition, comprising: mixing the engineered nanobody according to claim 1 with a liposome composition; and forming 100 nm liposomes from the liposome composition, having between 200 to 2500 chimeric nanobodies per 100 nm liposome. An engineered nanobody conjugate is provided comprising an ordered sequence of a peptide affinity tag, a Variable Heavy domain of Heavy chain (VHH) nanobody, a peptide linker, a cysteine residue, and a peptide fatty acylation signal.